Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1624

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 13
Chunk 1624
---
 $76,000 and $78,000, respectively, for a ROU lease from a company controlled by the Company's CEO. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by both parties. On December 31, 2022, the Company executed a two-year lease extension through December 31, 2024 in accordance with the terms of the original lease agreement. Rents of approximately $30,000 was payable at September 30, 2024. No rent was payable at September 30, 2025.

The Company agreed to pay a monthly standby fee for the term of the Credit Agreement, which amounted to $4,000 in the year ending September 30, 2025 and $51,000 in the year ending September 30, 2024.

At September 30, 2025, accounts and other receivable included immaterial balance due from certain executive officers related to foreign exchange payroll adjustments recorded during fiscal 2025. These amounts are being recovered through scheduled deductions and are expected to be settled by December 2025. Other than these FX-related adjustments, the Company did not have any loans or other receivables outstanding from its directors or executive officers as of September 30, 2025.

F-24

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

13. Subsequent events

Subsequent to September 30, 2025, the Company sold a total of 1,177,568 common shares pursuant to the HCW ATM agreement with H.C. Wainwright & Co., LLC for net proceeds of approximately $3.4 million, after deducting sales agent commissions. In addition, subsequent to September 30, 2025, the Company granted an aggregate of 21,642 restricted share units under its equity incentive plan. During the same period, 14,472 RSUs were settled in an equivalent number of common shares. Subsequent to September 30, 2025, the Company entered into certain service agreements with third-party service providers related to its research and development activities. Under the terms of these agreements, the Company may be required to make future payments of up to an aggregate of approximately $4.2 million, contingent upon the scope of services performed and terms of the underlying agreements.

F-25